Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Feb. 04, 2020	Sep. 05, 2018	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Class of Stock [Line Items]
Equity issuance costs				$ 729
Preferred stock, shares outstanding
Proceeds from warrants exercised				$ 51
Warrant [Member]
Class of Stock [Line Items]
Number of shares issued for common stock				18,889
Number of warrants exercised				18,889
Proceeds from warrants exercised				$ 51
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding		150,000
Proceeds from indebtedness		$ 250
Series A Preferred Stock Purchase Agreement [Member] | Specialty Renal Products, Inc. [Member]
Class of Stock [Line Items]
Sale of common stock		600,000
Proceeds from sale of stock value		$ 3,000
Sale of stock price per share		$ 5.00
Equity issuance costs		$ 30
Equity interest		62.50%
Ownership percentage		100.00%
Dividends per share rate		$ 0.40
Series A Preferred Stock Purchase Agreement [Member] | Specialty Renal Products, Inc. [Member] | Entities Controlled by Member of Management [Member]
Class of Stock [Line Items]
Number of shares issued for common stock		18,000
Series A Preferred Stock Purchase Agreement [Member] | Specialty Renal Products, Inc. [Member] | Largest Shareholder [Member]
Class of Stock [Line Items]
Number of shares issued for common stock		400,000
Series A Preferred Stock Purchase Agreement [Member] | Holders of Series A Preferred [Member] | Specialty Renal Products, Inc. [Member]
Class of Stock [Line Items]
Equity interest		37.50%
Ownership percentage		100.00%
Underwritten Public Offering [Member]
Class of Stock [Line Items]
Sale of common stock	937,500
Proceeds from sale of stock value	$ 7,500
Sale of stock price per share	$ 8.00
Proceeds from net of equity issuance cost	$ 700
Proceeds from public offering	$ 6,800